GMP – Page 96 – Pharma.Tips

Supplier change not evaluated during routine operations – regulatory expectations for material changes

Navigating Supplier Changes: Evaluating Material Modifications During Routine Operations In today’s stringent regulatory environment, the integrity of raw materials and the robustness of change control processes are paramount for pharmaceutical…

Critical supplier risk not assessed during supply disruption – how to prevent repeat supplier failures

Assessing Critical Supplier Risks During Supply Disruptions: A Comprehensive Investigation Guide In the pharmaceutical manufacturing landscape, supply disruptions pose significant risks that can jeopardize product quality and compliance. One critical…

Supplier change not evaluated during supplier change – preventing batch rejection and recalls

Preventing Batch Rejections and Recalls Due to Unassessed Supplier Changes In the pharmaceutical manufacturing environment, supplier changes can have serious repercussions. If a supplier change is not properly evaluated, it…

Audit response ineffective during supply disruption – how to prevent repeat supplier failures

How to Address Ineffective Audit Responses During Supply Disruptions to Prevent Future Failures In the dynamic world of pharmaceutical manufacturing, supply disruptions can lead to serious operational challenges, especially when…

Change control documentation gaps during regulatory inspection – preventing batch rejection and recalls

Addressing Documentation Gaps in Change Control During Regulatory Inspections In the high-stakes environment of pharmaceutical manufacturing, managing change control is critical to maintaining compliance and ensuring product quality. Documentation gaps…

Quality agreement gaps during requalification – inspection questions regulators ask

Identifying Quality Agreement Gaps during Requalification: A Practical Investigation Guide When it comes to maintaining the integrity of pharmaceutical manufacturing, the importance of vendor qualification and the nuances of quality…

Change control documentation gaps during routine operations – risk-based change impact assessment

Addressing Documentation Gaps in Change Control During Routine Operations Pharmaceutical manufacturing is an intricate process, reliant on precise documentation and strict adherence to regulatory standards. Change control documentation gaps during…

Vendor change implemented without approval during requalification – audit CAPA remediation framework

Investigation of Unauthorized Vendor Change During Material Requalification In the pharmaceutical manufacturing realm, the implementation of changes regarding raw materials or vendors without prior approval can lead to severe consequences,…

Unapproved material substitution during deviation investigation – regulatory expectations for material changes

Addressing Unapproved Material Substitution in Deviation Investigations: A Playbook for Pharma Professionals In the pharmaceutical manufacturing landscape, unapproved material substitution during deviation investigations can pose critical compliance and safety risks.…

Tag: GMP